Proteomics in liver fibrosis is more than meets the eye

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 5, 2008, Pages 450-464

  Cheung, Kin Jip ^a   Tilleman, Kelly ^b   Deforce, Dieter ^b   Colle, Isabelle ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Biomarker; Extracellular matrix; Liver biopsy; Liver fibrosis; Proteins; Proteomics; Serum

Indexed keywords

ANALYTIC METHOD; CLINICAL STUDY; DIAGNOSTIC PROCEDURE; EXPERIMENTAL STUDY; FRACTIONATION; HUMAN; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; RELIABILITY; REVIEW; STATISTICAL ANALYSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; PROTEINS; PROTEOMICS;

EID: 42149181227     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f4de92     Document Type: Review

References (136)

1. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006; 364:33-60.
2. Jansen PL. Nonalcoholic steatohepatitis. Neth J Med 2004; 62:217-224.
3. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004; 10:S21-S29.
4. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. Faseb J 2001; 15:1335-1349.
5. Burroughs A, McNamara D. Liver disease in Europe. Aliment Pharmacol Ther 2003; 18 (Suppl 3):54-59.
6. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non- alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004; 18:1089-1104.
7. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218.
8. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247-2250.
9. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 (Suppl 1):S38-S53.
10. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 (Suppl 1):S59-S67.
11. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21:311-335.
12. Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc 2004; 37:3-15.
13. Eng FJ, Friedman SL. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000; 279:G7-G11.
14. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21:351-372.
15. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92:827-839.
16. Anand BS. Cirrhosis of liver. West J Med 1999; 171:110-115.
17. Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998; 74:193-202.
18. Osterreicher CH, Stickel F, Brenner DA. Genomics of liver fibrosis and cirrhosis. Semin Liver Dis 2007; 27:28-43.
19. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
20. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53:451-455.
21. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
22. Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43:568-571.
23. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
24. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38:427-432.
25. Cholongitas E, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006; 125:710-721.
26. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906.
27. Skripenova S, Trainer TD, Krawitt EL, Blaszyk H. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007; 60:321-324.
28. Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 2006; 43:373-374; author reply 5-6.
29. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55:403-408.
30. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174.
31. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7:d793-d807.
32. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
33. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
34. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
35. Pinzani M. Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched. Gut 2006; 55:310-312.
36. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12:3682-3694.
37. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10:429-434.
38. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev 2002; 66:39-63; table of contents.
39. Diamond DL, Proll SC, Jacobs JM, Chan EY, Camp DG II, Smith RD, et al. HepatoProteomics: applying proteomic technologies to the study of liver function and disease. Hepatology 2006; 44:299-308.
40. Hanash S. Disease proteomics. Nature 2003; 422:226-232.
41. Parent R, Beretta L. Proteomics in the study of liver pathology. J Hepatol 2005; 43:177-183.
42. Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, et al. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol 2003; 21:566-569.
43. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 2006; 1:2650-2660.
44. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006; 5:651-658.
45. Boehm AM, Putz S, Altenhofer D, Sickmann A, Falk M. Precise protein quantification based on peptide quantification using iTRAQ. BMC Bioinformatics 2007; 8:214.
46. Rivers J, Simpson DM, Robertson DH, Gaskell SJ, Beynon RJ. Absolute multiplexed quantitative analysis of protein expression during muscle development using QconCAT. Mol Cell Proteomics 2007; 6:1416-1427.
47. Li S, Zeng D. CILAT-a new reagent for quantitative proteomics. Chem Commun (Camb) 2007; 21:2181-2183.
48. Kennedy S. Proteomic profiling from human samples: the body fluid alternative. Toxicol Lett 2001; 120:379-384.
49. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250:4007-4021.
50. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004; 4:3665-3685.
51. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001; 1:377-396.
52. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18:2071-2077.
53. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006; 312:212-217.
54. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 2001; 18:2071-2077.
55. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003; 21:255-261.
56. Bischoff R, Luider TM. Methodological advances in the discovery of protein and peptide disease markers. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 803:27-40.
57. Chich JF, David O, Villers F, Schaeffer B, Lutomski D, Huet S. Statistics for proteomics: experimental design and 2-DE differential analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 849:261-272.
58. Hanash SM. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 2000; 21:1202-1209.
59. Veenstra TD. Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847:3-11.
60. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17:994-999.
61. Unwin RD, Evans CA, Whetton AD. Relative quantification in proteomics: new approaches for biochemistry. Trends Biochem Sci 2006; 31:473-484.
62. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005; 4:1487-1502.
63. Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5:1338-1347.
64. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDI-TOF MS for diagnostic proteomics. Anal Chem 2003; 75:148A-155A.
65. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 2005; 230:95-106.
66. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF III. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 2006; 208:595-606.
67. Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006; 5:310-320.
68. Nielsen UB, Geierstanger BH. Multiplexed sandwich assays in microarray format. J Immunol Methods 2004; 290:107-120.
69. Asselah T, Bieche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27:13-27.
70. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27:44-54.
71. Utsunomiya T, Okamoto M, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, et al. A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol 2007; 13:383-390.
72. Maher JJ, Bissell DM, Friedman SL, Roll FJ. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest 1988; 82:450-459.
73. Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tateno C, Seki S, et al. Proteome analysis of rat hepatic stellate cells. Hepatology 2000; 32:268-277.
74. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol 2005; 39:S158-S161.
75. Cassiman D, Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J Hepatol 2002; 37:527-535.
76. Gutierrez-Ruiz MC, Gomez-Quiroz LE. Liver fibrosis: searching for cell model answers. Liver Int 2007; 27:434-439.
77. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54:142-151.
78. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21:373-384.
79. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21:397-416.
80. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999; 14:618-633.
81. Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, et al. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int J Biochem Cell Biol 2006; 38:135-151.
82. Kawada N. Molecular mechanism of stellate cell activation and therapeutic strategy for liver fibrosis. Comp Hepatol 2004; 3 (Suppl 1):S3.
83. Kawada N, Kristensen DB, Asahina K, Nakatani K, Minamiyama Y, Seki S, et al. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem 2001; 276:25318-25323.
84. Kang JS, Wanibuchi H, Morimura K, Puatanachokchai R, Salim EI, Hagihara A, et al. Enhancement by estradiol 3-benzoate in thioacetamideinduced liver cirrhosis of rats. Toxicol Sci 2005; 85:720-726.
85. Tateaki Y, Ogawa T, Kawada N, Kohashi T, Arihiro K, Tateno C, et al. Typing of hepatic nonparenchymal cells using fibulin-2 and cytoglobin/STAP as liver fibrogenesis-related markers. Histochem Cell Biol 2004; 122:41-49.
86. Petrak J, Myslivcova D, Man P, Cmejla R, Cmejlova J, Vyoral D. Proteomic analysis of iron overload in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1059-G1066.
87. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 2004; 99:286-291.
88. Jacobs JM, Diamond DL, Chan EY, Gritsenko MA, Qian W, Stastna M, et al. Proteome analysis of liver cells expressing a full-length hepatitis C virus (HCV) replicon and biopsy specimens of posttransplantation liver from HCV-infected patients. J Virol 2005; 79:7558-7569.
89. Sato S, Fukasawa M, Yamakawa Y, Natsume T, Suzuki T, Shoji I, et al. Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem (Tokyo) 2006; 139:921-930.
90. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117:539-548.
91. Henkel C, Roderfeld M, Weiskirchen R, Scheibe B, Matern S, Roeb E. Identification of fibrosis-relevant proteins using DIGE (difference in gel electrophoresis) in different models of hepatic fibrosis. Z Gastroenterol 2005; 43:23-29.
92. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci U S A 2003; 100:3065-3070.
93. Petrak J, Myslivcova D, Halada P, Cmejla R, Cmejlova J, Vyoral D, et al. Iron-independent specific protein expression pattern in the liver of HFE-deficient mice. Int J Biochem Cell Biol 2007; 39:1006-1015.
94. Venkatraman A, Landar A, Davis AJ, Chamlee L, Sanderson T, Kim H, et al. Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. J Biol Chem 2004; 279:22092- 22101.
95. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40:860-867.
96. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102:538-549.
97. Liu EH, Chen MF, Yeh TS, Ho YP, Wu RC, Chen TC, et al. A useful model to audit liver resolution from cirrhosis in rats using functional proteomics. J Surg Res 2007; 138:214-223.
98. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006; 13:297-302.
99. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007; 381:107-113.
100. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100:616-623.
101. Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL Jr, et al. Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007; 46:649-657.
102. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-867.
103. Gravel P, Walzer C, Aubry C, Balant LP, Yersin B, Hochstrasser DF, et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochem Biophys Res Commun 1996; 220:78-85.
104. Solter PF. Clinical pathology approaches to hepatic injury. Toxicol Pathol 2005; 33:9-16.
105. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2:1096-1103.
106. Henry H, Tissot JD, Messerli B, Markert M, Muntau A, Skladal D, et al. Microheterogeneity of serum glycoproteins and their liver precursors in patients with carbohydrate-deficient glycoprotein syndrome type I: apparent deficiencies in clusterin and serum amyloid P. J Lab Clin Med 1997; 129:412-421.
107. Arndt T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem 2001; 47: 13-27.
108. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel Serum Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients. 2007. DOI: 10.1373/clinchem.2007.089144.
109. Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005; 51:328-335.
110. Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol 2004; 10:2327-2329.
111. Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006; 12:7604-7612.
112. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42:665-674.
113. Kam RK, Poon TC, Chan HL, Wong N, Hui AY, Sung JJ. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis. Clin Chem 2007; 53:1254-1263.
114. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003; 3:1345-1364.
115. Hanash S. HUPO initiatives relevant to clinical proteomics. Mol Cell Proteomics 2004; 3:298-301.
116. Malmstrom J, Westergren-Thorsson G, Marko-Varga G. A proteomic approach to mimic fibrosis disease evolvement by an in vitro cell line. Electrophoresis 2001; 22:1776-1784.
117. Westergren-Thorsson G, Malmstrom J, Marko-Varga G. Proteomics - the protein expression technology to study connective tissue biology. J Pharm Biomed Anal 2001; 24:815-824.
118. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117:524-529.
119. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, et al. A proteomic analysis of human bile. Mol Cell Proteomics 2004; 3:715-728.
120. Stark M, Jornvall H, Johansson J. Isolation and characterization of hydrophobic polypeptides in human bile. Eur J Biochem 1999; 266:209-214.
121. Melle C, Kaufmann R, Hommann M, Bleul A, Driesch D, Ernst G, et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 2004; 24:885-891.
122. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41:634-642.
123. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333-342.
124. Amacher DE, Adler R, Herath A, Townsend RR. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005; 51:1796-1803.
125. Danta M, Dore GJ, Hennessy L, Li Y, Vickers CR, Harley H, et al. Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection. Med J Aust 2002; 177:240-245.
126. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36:S47-S56.
127. McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004; 53:318-321.
128. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55:569-578.
129. Shaw MM, Riederer BM. Sample preparation for two-dimensional gel electrophoresis. Proteomics 2003; 3:1408-1417.
130. Ayache S, Panelli M, Marincola FM, Stroncek DF. Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am J Clin Pathol 2006; 126:174-184.
131. Hulmes JD, Bethea D, Ho K, Huang SP, Ricci DL, Opiteck GJ, et al. Serum/plasma proteome: an investigation of plasma collection, stabilization and storage procedures for proteomic analysis of clinical samples. Clin proteomics 2004; 1:17-32.
132. Bodovitz S, Joos T. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets. Trends Biotechnol 2004; 22:4-7.
133. Meleth S, Deshane J, Kim H. The case for well-conducted experiments to validate statistical protocols for 2D gels: different pre-processing=different lists of significant proteins. BMC Biotechnol 2005; 5:7.
134. Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Paez de la Cadena M. Improvements in the search for potential biomarkers by proteomics: application of principal component and discriminant analyses for two-dimensional maps evaluation. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 849:251-260.
135. Domon B, Aebersold R. Challenges and opportunities in proteomics data analysis. Mol Cell Proteomics 2006; 5:1921-1926.
136. Duncan MW, Hunsucker SW. Proteomics as a tool for clinically relevant biomarker discovery and validation. Exp Biol Med (Maywood) 2005; 230:808-817.